Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03447054
Other study ID # Baudoin_2016_J1130650_206500
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date September 1, 2020

Study information

Verified date November 2020
Source Brugmann University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Most severe forms of alcohol-use disorder are thought to reflect an abnormal interplay between two neural systems: an overly active impulsive one driven by immediate rewards prospects and a weak reflective one, tuned on long-term prospects. The investigators propose that two non-pharmacological interventions, Transcranial Direct Current Stimulation (tDCS) and Inhibitory Control Techniques (ICT) may act on both systems when combined, which might ultimately result is a reduction of alcohol relapse rate.


Description:

Treating Alcohol dependence remains notoriously difficult despite use of several medications, psychotherapeutic and psychosocial interventions. Alcohol dependence is thought to reflect an abnormal interplay between two neural systems: an overly active impulsive one driven by immediate rewards prospects and a weak reflective one, tuned on long-term prospects. The investigators proposes that two non-pharmacological interventions, Transcranial Direct Current Stimulation (tDCS) and Inhibitory Control Techniques (ICT) may act on both systems when combined. tDCS has been found to improve working memory, which is necessary to evaluate long-term consequences of actions. ICT is able to modify the automatic approach tendencies towards appetitive cues. The investigators will recruit 160 alcohol-dependent patients and divide them randomly between four treatment conditions : real transcranial Direct Current Stimulation (tDCS) with active or control Inhibitory Control Technique (ICT ); or sham (placebo) tDCS with active or control ICT. Patients will be evaluated with primary outcome measures (alcohol consumption patterns) and secondary outcome measures (working memory and changes in alcohol-related stimuli affective values).


Recruitment information / eligibility

Status Completed
Enrollment 136
Est. completion date September 1, 2020
Est. primary completion date March 18, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients with severe alcohol-use disorder (DSM-5 criteria), hospitalized for detoxification. - Severity of alcohol use disorder must be at least moderate (at least 4 DSM-5 criteria) - Aged between 18 and 65 years - Comorbidity with anxiety disorders and depressive disorders is allowed - Patients must be illegal drug free for 3 weeks at beginning of trial - Pharmacotherapy: patients should be benzodiazepines free at the moment of inclusion. They are allowed to continue other psychotropic medication (antidepressants, antipsychotics, mood stabilizers), providing they are following a stable regimen that will not be changed during the protocol time. - Patients must be reachable for follow-up Exclusion Criteria: - Previous neurological conditions (epilepsy, traumatic brain injury, stroke) - Present delirium, confusion or severe cognitive disorder - Schizophrenia, chronic psychotic disorders, bipolar type 1 disorder. - Any severe, life-threatening disorders - High suicidal risk - Specific contraindications for tDCS: metallic plates in the head - Alcohol medication treatment initiated during the rehab: acamprosate, disulfiram, baclofen, nalmefen.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Combined TDCS active and ICT active
Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
Combined TDCS sham and ICT active
Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
Combined TDCS active and ICT inactive
Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
Combined Sham TDCS and inactive ICT
Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days

Locations

Country Name City State
Belgium CHU-Brugmann Brussels

Sponsors (3)

Lead Sponsor Collaborator
Brugmann University Hospital Université Libre de Bruxelles, University Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of alcohol use in post-treatment at week 2 Based on self-report questionnaires (grams of ethanol/occasion, per/day, number of consecutive days of alcohol drinking) é weeks post-rehab
Primary Reduction of alcohol use in post-treatment at week 4 Based on self-report questionnaires (grams of ethanol/occasion, per/day, number of consecutive days of alcohol drinking) 4 weeks post-rehab
Primary Reduction of the relapse rate in post-treatment at week 2 Based on self-report questionnaires and on one other significant person's feedback; binary outcome (relapser or non-relapser) 2 weeks post-rehab
Primary Reduction of the relapse rate in post-treatment at week 4 Based on self-report questionnaires and on one other significant person's feedback; binary outcome (relapser or non-relapser) 4 weeks post-rehab
Primary Reduction of alcohol use in post-treatment at week 12 Based on self-report questionnaires (grams of ethanol/occasion, per/day, number of consecutive days of alcohol drinking) 12 weeks post-rehab
Primary Reduction of the relapse rate in post-treatment at week 12 Based on self-report questionnaires and on one other significant person's feedback; binary outcome (relapser or non-relapser) 12 weeks post-rehab
Primary Reduction of alcohol use in post-treatment at week 24 Based on self-report questionnaires (grams of ethanol/occasion, per/day, number of consecutive days of alcohol drinking) 24 weeks post-rehab
Primary Reduction of the relapse rate in post-treatment at week 24 Based on self-report questionnaires and on one other significant person's feedback; binary outcome (relapser or non-relapser) 24 weeks post-rehab
Secondary Cue reactivity (attractiveness) at day 22 measures of attractiveness of used and novel alcohol-related pictures: Likert scale ranging from not (score of 0) at all to very much (score of 9) at post-intervention (day 22 of hospitalization)
Secondary Cue reactivity at day 22 measures of attractiveness of used and novel alcohol-related pictures: Likert scale ranging from not (score of 0) at all to very much (score of 9) at post-intervention (day 22 of hospitalization)
Secondary Cue reactivity (valence) at day 22 emotional content (valence) of pictures used in the response inhibition practice and of new pictures. Likert scale ranging from not (score of 0) at all to very much (score of 9) at post-intervention (day 22 of hospitalization)
Secondary Cue reactivity (arousal) at day 22 emotional content (arousal) of pictures used in the response inhibition practice and of new pictures. Likert scale ranging from not (score of 0) at all to very much (score of 9) at post-intervention (day 22 of hospitalization)
Secondary Cue reactivity (alcohol verbal fluency) at day 12 Alcohol verbal fluency (from Goldstein et al., 2007; Drug and Alcohol Dependence, 89:97-101 and Hon et al., 2016, Psychopharmacology, 233: 851-861: Participants are instructed to name as many alcohol-related words as possible in 1 min. Responses were audio recorded and independently coded into three categories: neutral, positive and negative valence by two researchers. at baseline (day 12 of hospitalization)
Secondary Cue reactivity (alcohol verbal fluency) at day 22 Alcohol verbal fluency (from Goldstein et al., 2007; Drug and Alcohol Dependence, 89:97-101 and Hon et al., 2016, Psychopharmacology, 233: 851-861: Participants are instructed to name as many alcohol-related words as possible in 1 min. Responses were audio recorded and independently coded into three categories: neutral, positive and negative valence by two researchers. at post-intervention (day 22 of hospitalization)
Secondary response inhibition at day 12 stop signal task (Logan, 1994): Stop Signal Reaction Time measure at baseline (day 10 of hospitalization)
Secondary response inhibition at day 22 stop signal task (Logan, 1994): Stop Signal Reaction Time measure at post-intervention (day 22 of hospitalization)
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A

External Links